AiCuris’ novel resistance breaking HIV compound AIC292 in phase I

05-Jul-2010 - Germany

AiCuris announced that its resistance-breaking NNRTI (Non-Nucleosidic Reverse Transcriptase Inhibitor) for HIV has entered human phase I clinical trials.

Following oral administration the compound was generally well tolerated and the resulting pharmacokinetic profile was indicative of the potential for a once daily dosing regime. Commenting on the results Prof. Dr. Helga Rübsamen-Schaeff, CEO of AiCuris, stated ‘’We are very pleased about these results. Due to the chronic course of an HIV infection once daily dosing is one of the key prerequisites for a modern HIV drug in addition to good efficacy and tolerability.”

Like other compounds from AiCuris, AIC292 has a resistance-breaking profile. Prof. Rübsamen-Schaeff: “With this compound we have demonstrated once again the ability to generate innovative and attractive candidates for clinical development with our in house research in collaboration with external partners.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances